2227. Short-Duration of Direct-Acting Antivirals in Hepatitis C Virus-Infected Cancer Patients

BACKGROUND: Short-duration with an 8-week course of ledipasvir/sofosbuvir (LDV/SOF) or glecaprevir/pibrentasvir (GLE/PIB) is considered adequate to treat hepatitis C virus (HCV) infection in selected patients. However, immunocompromised patients with HCV/HIV are not eligible for this approach. Herei...

Descripción completa

Detalles Bibliográficos
Autores principales: Hosry, Jeff, Angelidakis, Georgios, Granwehr, Bruno, Torres, Harrys
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253132/
http://dx.doi.org/10.1093/ofid/ofy210.1880

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253132/
http://dx.doi.org/10.1093/ofid/ofy210.1880

Ejemplares similares